Literature DB >> 7503934

Pseudosarcomatous fibromyxoid tumor of the urinary bladder and prostate: immunohistochemical, ultrastructural, and DNA flow cytometric analyses of nine cases.

J Y Ro1, A K el-Naggar, M B Amin, A A Sahin, N G Ordonez, A G Ayala.   

Abstract

Pseudosarcomatous fibromyxoid tumor of the genitourinary tract is a rare pathologic entity of hitherto unknown etiology that, because of the cellular pleomorphism and the infiltrative nature of the lesion, may be mistakenly diagnosed as sarcomatoid carcinoma or sarcoma. We retrospectively studied nine pseudosarcomatous fibromyxoid tumors involving the bladder and prostate to define characteristic parameters that may allow for accurate diagnosis. The study patients included four men and five women with a mean age of 48.7 years. Histologic analysis revealed myxoid lesions with a proliferation of spindle fibroblastic cells in a background of granulation tissue-type vascularity and inflammatory cells. Mitoses were infrequent and no atypical forms were found. Immunostaining was positive for vimentin and smooth muscle actin, and negative for S-100 protein, desmin, myoglobin, and keratin. Ultrastructurally, the lesion displayed fibroblastic and myofibroblastic cell features. Flow cytometric DNA content analysis revealed uniform DNA diploidy and a low S-phase fraction. All patients were alive and well with no evidence of disease after a mean follow-up of 4.8 years. In contrast, the sarcomatoid carcinomas and sarcomas of the urinary bladder and prostate that were used as controls occurred in older patients and had more frequent mitoses with atypical forms, tumor-type necrosis, and different immunostaining profiles; they were preponderantly aneuploid or diploid with high S-phase fraction. Awareness of the clinicopathologic and biologic characteristics of these lesions is necessary to ensure their accurate diagnosis and to prevent unnecessary radical therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7503934     DOI: 10.1016/0046-8177(93)90217-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

Review 1.  Fibromyxoma of the small bowel: a review.

Authors:  Meenakshi Chaku; Ehab Elakkary; Fabiana El Sarraf; Thanh Phan
Journal:  Dig Dis Sci       Date:  2007-03-14       Impact factor: 3.199

Review 2.  A Rare Case of Inflammatory Myofibroblastic Tumor of the Prostate and Review of the Literature.

Authors:  Min Seok Kim; Sung-Chul Lim
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Inflammatory pseudotumor of urinary bladder - a diagnostic and management dilemma.

Authors:  Anup Kumar; Sahibinder S Bhatti; Sachit Sharma; Siddharth D Gupta; Rajeev Kumar
Journal:  Int Urol Nephrol       Date:  2007-02-27       Impact factor: 2.370

4.  Low-grade pelvic masses with spindle cell and fibroblastic proliferation: a case report.

Authors:  John Micha; Mark Rettenmaier; Douglas Ellison; John Brown; Bram Goldstein
Journal:  J Med Case Rep       Date:  2007-05-02

5.  Embryonal rhabdomyosarcoma of the adult urinary bladder: a rare case report of misclassification as inflammatory myofibroblastic tumor.

Authors:  Kelven Weijing Chen; Fiona Mei Wen Wu; Victor Kwan Min Lee; Kesavan Esuvaranathan
Journal:  Case Rep Surg       Date:  2015-02-09

6.  Polypoid Carcinoma of the Oropharynx with Stromal Ossifying Myofibroblastic Proliferation: A Case Report and Literature Review.

Authors:  Marcello Filotico; Alessandro D'Amuri
Journal:  Case Rep Pathol       Date:  2016-12-05

7.  Development and validation of a prognostic nomogram for predicting overall survival in patients with primary bladder sarcoma: a SEER-based retrospective study.

Authors:  Shijie Li; Xuefeng Liu; Xiaonan Chen
Journal:  BMC Urol       Date:  2021-11-25       Impact factor: 2.264

8.  Clinico-radiological and Pathological Characteristics of Inflammatory Myofibroblastic Tumors in Children: A Retrospective Study.

Authors:  Mohamad Hussain Mir; Waseem Dar; Sheikh Aejaz Aziz; Gul Mohamad; Burhan Wani
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.